Production (Stage)
Opus Genetics, Inc.
IRD
$1.04
$0.044.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.65M | 10.99M | 8.38M | 16.45M | 19.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.65M | 10.99M | 8.38M | 16.45M | 19.01M |
| Cost of Revenue | 30.49M | 27.34M | 24.26M | 18.76M | 17.40M |
| Gross Profit | -16.84M | -16.35M | -15.88M | -2.31M | 1.61M |
| SG&A Expenses | 19.95M | 18.22M | 14.20M | 13.36M | 14.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.95M | 45.07M | 37.86M | 31.53M | 31.15M |
| Operating Income | -36.30M | -34.07M | -29.47M | -15.08M | -12.14M |
| Income Before Tax | -58.62M | -57.53M | -27.19M | -14.09M | -11.29M |
| Income Tax Expenses | -- | -- | -2.00K | 12.00K | 12.00K |
| Earnings from Continuing Operations | -58.62 | -57.53 | -27.19 | -14.11 | -11.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.62M | -57.53M | -27.19M | -14.11M | -11.30M |
| EBIT | -36.30M | -34.07M | -29.47M | -15.08M | -12.14M |
| EBITDA | -36.28M | -34.07M | -29.47M | -15.07M | -12.13M |
| EPS Basic | -1.99 | -2.04 | -1.09 | -0.54 | -0.48 |
| Normalized Basic EPS | -0.67 | -0.70 | -0.68 | -0.34 | -0.30 |
| EPS Diluted | -1.99 | -2.04 | -1.09 | -0.55 | -0.49 |
| Normalized Diluted EPS | -0.67 | -0.70 | -0.68 | -0.34 | -0.30 |
| Average Basic Shares Outstanding | 116.22M | 106.85M | 99.49M | 94.79M | 89.92M |
| Average Diluted Shares Outstanding | 116.22M | 106.85M | 99.49M | 95.75M | 90.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |